1694379447_100923-TN23-Lung-(2).png

Promising Results: Perioperative Durvalumab with Neoadjuvant Chemotherapy Improves Pathological Complete Response and Event-Free Survival in Resectable NSCLC- Phase III AEGEAN Trial

Sep 10, 2023

table {mso-displayed-decimal-separator:"\."; mso-displayed-thousand-separator:"\,";} tr {mso-height-source:auto;} col {mso-width-source:auto;} td {padding-top:1px; padding-right:1px; padding-left:1px; mso-ignore:padding; color:black; font-size:11.0pt; font-weight:400; font-style:normal; text-decoration:none; font-family:Calibri, sans-serif; mso-font-charset:0; text-align:general; vertical-align:bottom; border:none; white-space:nowrap; mso-rotate:0;} .xl32 {font-family:Arial, sans-serif; mso-font-charset:0; vertical-align:middle; border:.5pt solid black; white-space:normal;}

Promising Results: Perioperative Durvalumab with Neoadjuvant Chemotherapy Improves Pathological Complete Response and Event-Free Survival in Resectable NSCLC- Phase III AEGEAN Trial